- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02104440
Clinical Trial In The Treatment Of Allogeneic Post-Transplant Cytopenias With Sequential Infusion Of Allogeneic Mesenchymal Cells Expanded In Vitro
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Salamanca/Castilla León
-
Salamanca, Salamanca/Castilla León, Spain, 37007
- University Clinical Hospital of Salamanca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients with hematologic malignancies who have been subjected to allo-HSCT and that are diagnosed with one or more peripheral cytopenias with complete chimerism in bone marrow (determined by molecular-STR-studies). They may include:
- Patients who have received as a source of cells MO or SP
- Patients who have received cells from a related donor or unrelated HLA-matched
- Patients transplanted with myeloablative or non-myeloablative conditioning
- Adequate cardiac function assessed from a clinical point of view by the researcher, with no history of ischemic heart disease (angina or myocardial infarction) in the previous 6 months.
- Adequate pulmonary function assessed clinically without evidence of severe obstructive or restrictive lung disease.
- Patients between 18 and 70 years
- Signed informed consent
Exclusion Criteria:
- Patients whose haemopathy has not been controlled by the transplantation or is in progress at the time of treatment.
- Patients who do not have complete chimerism in bone marrow (performed within 28 days prior to baseline by molecular study -STR-).
- Patients with thrombotic microangiopathy.
- Patients with post-transplant cytopenias with toxic origin in relation to antiviral treatment (eg ganciclovir, valganciclovir) without concomitant graft against host disease.
- Patients with bacterial, viral or fungal infection that is not being controlled with proper treatment.
- Patients with a history of ischemic heart disease (angina or myocardial infarction) in the previous 6 months, and those considered by the investigator does not have adequate cardiac function, evaluated from a clinical point of view.
- Patients with poor lung function, evaluated clinically, according to the researcher.
- Patients who, in the opinion of the investigator, are not on a good position to tolerate treatment.
- Patients who do not have the required donor.
- Women pregnant or at risk of pregnancy by contraceptive measures inadequate.
- Patients <18 or > 70 years.
- Patients who did not sign the informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Patients with cytopenia after allo-HSCT
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse effects at the time of infusion and infections after infusion of MSC
Time Frame: During the period of infusion of the cells into the patient (an average of one hour)
|
All the adverse effects that may arise and possible toxicities (WHO grade) after infusion of the cells were collected.
|
During the period of infusion of the cells into the patient (an average of one hour)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mesenchymal cell efficiency in recovering cytopenia
Time Frame: Monitoring will be from the last infusion of MSCs to the patient until 90 days after the last administration
|
The efficiency is measured by the recovery of cytopenia after administration of MSC (depending on the original cytopenia) and may be of two types: Complete response:
Partial response:
|
Monitoring will be from the last infusion of MSCs to the patient until 90 days after the last administration
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Fermín Sánchez-Guijo Martín, Ph.D, University Clinical Hospital of Salamanca
- Principal Investigator: José Rifón Roca, Ph.D, University of Navarrra Hospital (Clinica Universitaria)
- Principal Investigator: José A Pérez Simón, Ph.D, Hospital Virgen del Rocío
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CSM/CIT
- 2013-000534-35 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cytopenia
-
Memorial Sloan Kettering Cancer CenterRecruitingClonal Cytopenia of Undetermined Significance | CCUS Clonal Cytopenia of Undetermined SignificanceUnited States
-
Washington University School of MedicineBristol-Myers Squibb; Damon Runyon Cancer Research FoundationNot yet recruitingClonal Cytopenia of Undetermined Significance | CCUS Clonal Cytopenia of Undetermined SignificanceUnited States
-
Children's Hospital Medical Center, CincinnatiCompletedAllogeneic Stem Cell Transplantation | Refractory Autoimmune Cytopenia(s)United States
-
Uma BorateRecruitingClonal Cytopenia of Undetermined SignificanceUnited States
-
Washington University School of MedicineGateway for Cancer Research; Servier Hellas Pharmaceuticals Ltd.RecruitingClonal Cytopenia of Undetermined SignificanceUnited States
-
Peking Union Medical College HospitalUnknownUmbilical Cord Blood | Refractory Immune CytopeniaChina
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingClonal Cytopenia of Undetermined Significance | Clonal Hematopoiesis of Indeterminate PotentialUnited States
-
National Institute of Allergy and Infectious Diseases...WithdrawnCTLA4 Haploinsufficency | Chronic CytopeniaUnited States
-
National Institutes of Health Clinical Center (CC)CompletedThrombocytopenia | Platelet Transfusion RefractorinessUnited States
-
Washington University School of MedicineRecruitingMyelodysplastic Syndromes | Clonal Cytopenia of Undetermined SignificanceUnited States
Clinical Trials on Sequential infusion of allogeneic mesenchymal stem cells expanded "in vitro"
-
Andalusian Network for Design and Translation of...Completed
-
Red de Terapia CelularHaematology Service,University Hospital of Salamanca, MªConsuelo del Cañizo... and other collaboratorsUnknown
-
LaTonya J. HicksonActive, not recruitingDiabetes Mellitus, Type 2 | Diabetes Mellitus | Chronic Kidney Diseases | Diabetes Mellitus, Type 1 | Diabetic NephropathiesUnited States
-
Supergenics Life Science Sdn. Bhd.Not yet recruitingDiabetic Foot Ulcer
-
Clinica Universidad de Navarra, Universidad de...CompletedIdiopathic Pulmonary FibrosisSpain
-
Universidad de la SabanaFundación Neumologica Colombiana; Stem Medicina Regenerativa; Innocell SASAvailablePulmonary Fibrosis | Pulmonary Hypertension | Systemic Sclerosis PulmonaryColombia
-
Mayo ClinicCompletedAtherosclerotic Renal Artery Stenosis | Ischemic Nephropathy | Renovascular HypertensionUnited States
-
Centre Hospitalier Universitaire, AmiensCompletedMyelodysplastic Syndromes | Hematopoietic Cell ProliferationFrance
-
Fundació Institut Germans Trias i PujolGermans Trias i Pujol HospitalCompleted
-
Instituto Nacional de Ciencias Medicas y Nutricion...Unknown